An argument based on the FDA’s sharing of purportedly confidential data will be hard to press insofar as Lovenox is no longer protected by a valid US patent, nor is it protected by Hatch-Waxman exclusivity for any indication.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”